OPKO and Entera Bio Present Dual GLP-1/Glucagon Tablet Candidate for Obesity and Metabolic Disorders

OPKO Health and Entera Bio plan to present an abstract for their dual GLP-1/glucagon tablet candidate, OPK-88006, at the ENDO 2025 annual meeting. The candidate is being developed for treating obesity and metabolic disorders in both oral tablet and weekly injectable forms. The companies aim to file an IND application with the FDA by the end of 2025, facilitating Phase 1 clinical trials. This development is seen as a significant milestone in the treatment landscape for metabolic disorders.

OPKO Health (NASDAQ: OPK) and Entera Bio (NASDAQ: ENTX) have announced that their abstract for the dual GLP-1/glucagon peptide treatment, OPK-88006, has been selected for presentation at the ENDO 2025 annual meeting in San Francisco. The candidate, being developed as both a once-daily tablet and a weekly subcutaneous injection, aims to treat obesity and metabolic disorders. The oral program combines OPKO's long-acting oxyntomodulin analog with Entera's N-Tab™ technology [1][2].

The presentation at ENDO 2025 will showcase new pharmacologic and pharmacokinetic in vivo data, providing crucial insights into the candidate's potential. The companies plan to file an Investigational New Drug (IND) application with the FDA later in 2025, followed by Phase 1 clinical studies [3].

OPK-88006 represents a significant advancement in the obesity therapeutics market, currently dominated by injectable GLP-1 agonists. The dual-mechanism approach, combining GLP-1 and glucagon activation, could potentially enhance metabolic benefits beyond what GLP-1 alone provides [1][2]. The oral delivery format, which addresses a critical gap in the current obesity treatment landscape, could offer improved patient acceptance and tolerability [2].

The collaboration between OPKO Health and Entera Bio leverages complementary technologies, with OPKO's oxyntomodulin analog and Entera's proprietary N-Tab™ oral delivery platform. This dual-format strategy could offer significant commercial advantages in the rapidly expanding GLP-1 market [2].

The companies' timeline indicates progression to IND filing later this year, positioning them at a pivotal inflection point. For Entera, this program represents validation of their oral peptide delivery technology in one of pharma's hottest therapeutic areas, potentially transforming the company's valuation if clinical development proceeds successfully [2].

Investors should recognize that this program remains in preclinical stages with years of clinical development required before potential commercialization. The upcoming presentation at ENDO 2025 will provide crucial insights into whether the pharmacokinetic data supports further development of this promising but early-stage candidate.

References:
[1] https://www.stocktitan.net/news/OPK/opko-health-and-entera-bio-abstract-for-first-in-class-dual-glp-1-buci39mc8xnv.html
[2] https://www.stocktitan.net/news/ENTX/opko-health-and-entera-bio-abstract-for-first-in-class-dual-glp-1-kdhwsp8nk9ig.html
[3] https://finance.yahoo.com/news/opko-health-entera-bio-abstract-120000380.html